{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:48Z","timestamp":1791357228145,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.schres.2018.02.058","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T05:52:03Z","timestamp":1519969923000},"page":"386-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Potentially fatal outcomes associated with clozapine"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-544X","authenticated-orcid":false,"given":"Kevin J.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Gurrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Delisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2018.02.058_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","article-title":"Cardiovascular adverse effects of antipsychotic drugs","volume":"23","author":"Buckley","year":"2000","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2018.02.058_bb0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2018.02.058_bb0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: A systematic review","volume":"192","author":"Clark","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2018.02.058_bb0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1192\/bjp.179.2.167","article-title":"Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication","volume":"179","author":"Cohen","year":"2001","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.02.058_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/JCP.0000000000000467","article-title":"Successful use of single doses of granulocyte-Colony stimulating factor (G-CSF) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report","volume":"36","author":"Comacchio","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2018.02.058_bb0035","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/tpj.2017.6","article-title":"More than 25years of genetic studies of clozapine-induced agranulocytosis","volume":"17","author":"de With","year":"2017","journal-title":"Pharmcogenomics J."},{"issue":"8","key":"10.1016\/j.schres.2018.02.058_bb0040","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40263-017-0448-6","article-title":"Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal 'Slow Gut' reactions, and comparison with international drug safety advice","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2018.02.058_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ebiom.2016.02.020","article-title":"Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study","volume":"5","author":"Every-Palmer","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.schres.2018.02.058_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40263-016-0391-y","article-title":"The Porirua Protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2018.02.058_bb0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.psychres.2017.06.068","article-title":"Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias","volume":"256","author":"Fabrazzo","year":"2017","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.schres.2018.02.058_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1176\/appi.ajp.2016.15101303","article-title":"G-CSF dosing to prevent recurrent clozapine-induced agranulocytosis","volume":"173","author":"Freeman","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.02.058_bb0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0000000000000458","article-title":"Aspiration pneumonia: an underappreciated risk of clozapine treatment","volume":"36","author":"Gurrera","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2018.02.058_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993\u20132003","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.schres.2018.02.058_bb0075","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/mol.114.091835","article-title":"Kinetics of drug interaction with the Kv11.1 potassium channel","volume":"85","author":"Hill","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.schres.2018.02.058_bb0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.seizure.2016.10.002","article-title":"Sudden death in epilepsy: insights from the last 25years","volume":"44","author":"Jones","year":"2017","journal-title":"Seizure"},{"issue":"Suppl. 9","key":"10.1016\/j.schres.2018.02.058_bb0085","first-page":"35","article-title":"Treatment-resistant schizophrenic patients","volume":"57","author":"Kane","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2018.02.058_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4322\/acr.2016.054","article-title":"Clozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death","volume":"6","author":"Katta","year":"2016","journal-title":"Autops. Case Rep."},{"key":"10.1016\/j.schres.2018.02.058_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2017.03.013","article-title":"Clozapine and incidence of myocarditis and sudden death - long term Australian experience","volume":"238","author":"Khan","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"9193","key":"10.1016\/j.schres.2018.02.058_bb0100","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.schres.2018.02.058_bb0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1532-5415.2007.01625.x","article-title":"Antipsychotic drug use and risk of pneumonia in elderly people","volume":"56","author":"Knol","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"10.1016\/j.schres.2018.02.058_bb0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/schbul\/sbr202","article-title":"Second-generation antipsychotic medications and risk of pneumonia in schizophrenia","volume":"39","author":"Kuo","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2018.02.058_bb0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JCP.0000000000000767","article-title":"The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review","volume":"37","author":"Lally","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2018.02.058_bb0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.bjp.0706744","article-title":"Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine","volume":"148","author":"Lee","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2018.02.058_bb0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.psym.2016.11.013","article-title":"Characterization of admission types in medically hospitalized patients prescribed clozapine","volume":"58","author":"Leung","year":"2017","journal-title":"Psychosomatics"},{"issue":"5","key":"10.1016\/j.schres.2018.02.058_bb0145","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e318267b3cd","article-title":"Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study","volume":"32","author":"Nielsen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2018.02.058_bb0150","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/pds.3804","article-title":"Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies","volume":"24","author":"Nose","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"10.1016\/j.schres.2018.02.058_bb0155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.schres.2018.02.058_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/acps.12827","article-title":"Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study","volume":"137","author":"Rohde","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.schres.2018.02.058_bb0165","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.02.058_bb0170","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.psym.2017.05.003","article-title":"Pneumonia can cause clozapine intoxication: a case report","volume":"58","author":"Ruan","year":"2017","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.schres.2018.02.058_bb0180","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.116.108035","article-title":"Beta-Arrestin-mediated regulation of the human ether-a-go-go-related gene potassium channel","volume":"92","author":"Sangoi","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.schres.2018.02.058_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"issue":"10","key":"10.1016\/j.schres.2018.02.058_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187034","article-title":"Biological substantiation of antipsychotic-associated pneumonia: systematic literature review and computational analyses","volume":"12","author":"Sultana","year":"2017","journal-title":"PLoS One"},{"issue":"9690","key":"10.1016\/j.schres.2018.02.058_bb0200","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.schres.2018.02.058_bb0205","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.schres.2018.02.058_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.genhosppsych.2017.02.004","article-title":"Clozapine induced gastrointestinal hypomotility: a potentially life threatening adverse event. A review of the literature","volume":"46","author":"West","year":"2017","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.schres.2018.02.058_bb0220","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","author":"Wimberley","year":"2017","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T10:39:21Z","timestamp":1564051161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418301385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"alternative-id":["S0920996418301385"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.02.058","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentially fatal outcomes associated with clozapine","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.02.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}